Neurocrine Biosciences, Inc. (Nasdaq: NBIX) revealed today its plans to showcase pivotal findings from the CAHtalyst™ Adult Phase 3 clinical study, shedding light on baseline characteristics of adults grappling with…
Viatris has just announced its financial outcomes for the initial quarter of 2024, showcasing sustained progress and the robustness of its core operations. Executive Insights Scott A. Smith, CEO of…
Shionogi & Co., Ltd. (based in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (headquartered in South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have finalized an…
argenx, a global leader in immunology dedicated to enhancing the lives of individuals grappling with severe autoimmune disorders, has unveiled its financial results for the first quarter of 2024 along…
CVS Health® Survey Highlights Growing Mental Health Concerns A recent survey conducted by CVS Health® (NYSE: CVS) in collaboration with Morning Consult reveals an alarming trend: concerns about mental health…
Bristol Myers Squibb (NYSE: BMY) has provided an update on its Phase 3 CheckMate -73L trial, revealing that it did not achieve its primary endpoint of progression-free survival (PFS) in…
Sanofi, in its pursuit of a robust vaccine portfolio, has forged a co-exclusive licensing agreement with Novavax, a biotech firm headquartered in Maryland, USA. The terms of this agreement encompass…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, reported today that the Phase 3 KEYNOTE-B21 trial assessing KEYTRUDA, Merck’s anti-PD-1 therapy, alongside chemotherapy as…
Total knee replacement surgery is a prevalent procedure, with approximately 790,000 surgeries performed annually in the U.S. This number is expected to rise due to factors like an aging population,…
Shionogi, in collaboration with Nagasaki University (Administrative Office: Nagasaki; President: Takeshi Nagayasu, M.D., Ph.D.), the National Institute of Infectious Diseases (Head Office: Shinjuku-ku, Tokyo; Director: Takashi Wakita), and the non-profit…
BeiGene, a leading global oncology firm, has unveiled its first-quarter 2024 results alongside significant business updates. John V. Oyler, Co-Founder, Chairman, and CEO at BeiGene, expressed satisfaction with the robust…
Lupin, a leading pharmaceutical company, has recently welcomed two distinguished individuals, Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta, to its Board as Independent Directors. Mr. Kindler boasts an illustrious…